VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 25, 2008) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") announces that it has received results from clinical tests of its T36® formulation ("T36®") for use as a skin antiseptic, a hygienic hand rub, a pre-surgical hand wash and a pre-injection scrub. In these clinical studies, T36® demonstrated complete efficacy after only 30 seconds of exposure to all 6 species of bacteria tested, including VRE (Vancomycin-Resistant Enterococcus), MRSA (Methicillin-Resistant Staphylococcus aureus) and MDR (Multi-Drug Resistant) Enterococcus faecium. These three species of bacteria are critical concerns in hospitals, nursing homes and other medical facilities based on their resistance to many antibiotics and other treatments. The clinical testing was completed according to the standards required by the FDA in the US, Health Canada and the European Medicines Agency, which included exposure of the bacteria to T36® for periods ranging from 30 seconds to 30 minutes.
